about
The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myelomaInhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cellsCommon variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma riskCharacterization of a transitional preplasmablast population in the process of human B cell to plasma cell differentiation.Modeling risk stratification in human cancer.GenomicScape: an easy-to-use web tool for gene expression data analysis. Application to investigate the molecular events in the differentiation of B cells into plasma cells.A new method for class prediction based on signed-rank algorithms applied to Affymetrix microarray experiments.Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays.Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma.Gene expression profiling and real-time PCR analyses identify novel potential cancer-testis antigens in multiple myeloma.Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells.Identification of pluripotent and adult stem cell genes unrelated to cell cycle and associated with poor prognosis in multiple myeloma.Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell linesThe glycome of normal and malignant plasma cellsInsulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma.A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma.Drug metabolism and clearance system in tumor cells of patients with multiple myelomaIdentification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myelomaChanges in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myelomaMicroarray-based understanding of normal and malignant plasma cells.Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma.Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myelomaInhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells.Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro.Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.Krüppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma.Identification of HLA-A2 restricted T-cell epitopes within the conserved region of the immunoglobulin G heavy-chain in patients with multiple myeloma.The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptorInhibition of aurora kinases for tailored risk-adapted treatment of multiple myelomaExpression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cellsDNA methylation score is predictive of myeloma cell sensitivity to 5-azacitidine.DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment.Thymosin beta4 in multiple myeloma: friend or foe.Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment.T cell-based targeted immunotherapies for patients with multiple myeloma.Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells.
P50
Q28391289-1D0BFB80-3C92-4FB8-A074-C7974E21BB07Q28487347-E2BF9483-0BDB-4090-ACDD-5DFE940CF170Q28943335-951B218E-05FB-4D3C-897D-EAA3A85C5711Q30485147-6DD122A3-54D6-4550-BD87-960871214351Q30486006-E47DB007-38E1-498B-A040-97DDE3DE3E4FQ30886634-BD47BADB-433B-4BA5-8190-6E548CC7594EQ33314438-A4D991D0-7B58-46C7-86D7-C1464A21515CQ33564854-F569F970-290C-415F-98E8-325B14C0537DQ33577408-69F8D135-C90A-4B65-9252-EC88D90C29BCQ33587558-09ACD348-8A7B-499F-B588-F4A5CF90AC06Q33691683-FF203CD4-F883-4407-8BF8-F28610DFB99AQ33952805-B954E923-5711-497B-88DE-428785A14568Q34104277-11D5AFB0-A425-4B26-B8D8-526FAF30E55BQ34364560-74010DCF-6183-4619-896D-575A0240D3E0Q34451553-7B5CF434-F8F0-4910-A2B4-F6AE2DC55C7CQ34750568-FF21F978-287F-4445-ADDE-26235971A1C3Q35080602-CF1A1CA9-47BD-41AF-9D23-43DD0E698A95Q35097641-EB4E5FD5-F636-418F-92A2-EC83675D60E0Q35669888-25332479-3752-47B2-A3C2-18926E005EE7Q35742560-A2334556-E9A3-43F0-945D-753D2AB73A65Q35880416-10B360CD-9982-4D77-A06E-3B3D11D898E3Q35944699-78620601-4EF1-4D6A-9A8A-39E5F874934DQ36366654-EABFBC9E-41DB-4D27-A886-FA311E9C51DCQ36453354-CF98E307-56CF-47FA-87C2-F142220BB482Q36499443-04683A83-C780-4ED3-BD77-CB530DB1A958Q36662044-0580B37F-1AB3-44C5-AFB8-417A2387F78AQ36782357-CB487F57-1C72-4A6E-9914-2A9C1195F338Q37012554-0CD9C710-A13C-4524-838C-61634F50D2E3Q37082345-D4FCE7CF-BDE1-4F9A-B5B8-01164C356094Q37144899-01F25156-3A54-4ECF-AF59-AA66BB8356FDQ37194598-7F5D9514-F1A5-4206-84EB-55A03354C220Q37215171-C4CD7F6A-6DFC-49C3-8616-99AA911D4EFBQ37237509-DAA27D4A-DDAE-4FD9-995F-037866170128Q37314430-1DE31790-B080-48ED-B821-5F5D5E603B2FQ37408128-35530769-7FBE-460B-9EE8-25CFEF3F0357Q37505517-7670C681-DF2E-4140-9363-372727F73E03Q37763974-306E9070-6B68-4615-91FE-6E5D07315533Q37867559-A36F8576-4E9B-4D4F-9989-5FA74D2E5B6FQ38246639-34BB7BE9-F31F-4F8C-A923-F1CC9AAC6C6AQ38329982-3EC65BA6-7515-487A-A3B1-3EAB4FDB2D06
P50
name
Dirk Hose
@ast
Dirk Hose
@en
Dirk Hose
@nl
type
label
Dirk Hose
@ast
Dirk Hose
@en
Dirk Hose
@nl
prefLabel
Dirk Hose
@ast
Dirk Hose
@en
Dirk Hose
@nl